Javeri Fiscal Services Ltd.

About Javeri

Equity

Derivatives

Mutual Funds

IPO

Corporate Info

Research

Contact Us

Corporate Info

Smart Quotes

Company Background

Board of Directors

Balance Sheet

Profit & Loss

Peer Comparison

Cash Flow

Shareholdings Pattern

Quarterly Results

Share Price

Deliverable Volume

Historical Volume

MF Holdings

Financial Ratios

Directors Report

Price Charts

Beta Analysis

Board Meetings

Corporate Announcements

Book Closure

Bonus

Company News

Dividend Details

Bulk Deals

Insider Trading

Advanced Chart

HOME > CORPORATE INFO > SMART QUOTES

Smart Quotes

Glenmark Pharmaceuticals Ltd.

Industry : Pharmaceuticals & Drugs

BSE Code	532296
ISIN Demat	INE935A01035
Book Value	858.31

NSE Code	GLENMARK
Dividend Yield %	0.13
Market Cap	545846.91

P/E	2616.34
EPS	0.74
Face Value	1


	BSE		NSE

06-Feb-2026

Last Price	1934.25
Net Change	-38.15
% Change	-1.93%
Prev.Close	1972.40
Open	1972.45
High	1972.45
Low	1911.60
Volume	7794

Last Price	1934.80
Net Change	-34.5
% Change	-1.75%
Prev.Close	1969.30
Open	1969.30
High	1969.30
Low	1911.00
Volume	490999

Value	15044230
Best Buy	0.00
Best Sell	0.00
Best Quantity	0
Sell Quantity	0
Today's Range	1972.45
52-Week High	2286.15
52-Week Low	1274.70

Value	947912075.3
Best Buy	0.00
Best Sell	1934.80
Best Quantity	0
Sell Quantity	1538
Today's Range	1969.30
52-Week High	2284.80
52-Week Low	1275.50

Open Price	1969.00
High Price	1969.00
Low Price	1912.70
Last Price	1937.30
Prev Close	1971.00
Change	-33.70
% Change	-1.71 %

Average Price	1931.96
Underlying Value	1934.80
Number of contracts traded	2880
Turnover in Rs. Lakhs	20865
Open Interest	11307000.00
Change in O I	88120.00
% Change in O I	0.79 %

Today

|

1W

|

1M

|

1Y

You need to upgrade your Flash Player

Best Bid

Best Offer

Quantity	0
Price	0.00

Quantity	0
Price	0.00

Best Bid

Best Offer

Quantity	0
Price	0.00

Quantity	1538
Price	1934.80

Best Bid

Best Offer

Quantity	750
Price	1938.7

Quantity	1125
Price	1940.7

Holding Details

Latest Corporate Events

Bonus

1 : 1

04-Mar-05

Book Closure

17-Sep-24

27-Sep-24

Dividend

250 %

03-Oct-25

Company News

19-01-2026

Glenmark Pharmaceuticals ...

05-01-2026

Glenmark Pharmaceuticals ...

23-12-2025

Glenmark Pharma’s arm lau...

23-12-2025

Glenmark Pharmaceuticals...

23-12-2025

Glenmark Pharma gains as ...

17-12-2025

Glenmark Pharmaceuticals’...

11-12-2025

Glenmark Pharma gains as ...

Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores

Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: Click Here.